J Clin Endocrinol Metab 2021 Jan 28. Epub 2021 Jan 28.
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Context: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery.
Methods: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy", "transdermal", "estradiol", "conjugated estrogens", "bioidentical", "cardiovascular disease", "lipoproteins", "glucose", "progestogens", "low dose".
Results: Available evidence indicates that oral unopposed estrogens have a favorable effect on lipoprotein levels, glycemia, insulin and CVD risk, however the addition of progestogens blunts the lipid-related effects. Read More